H.C. Wainwright upgraded Sarepta (SRPT) to Neutral from Sell with an unchanged price target of $75. The firm cites the stock’s current valuation “as in line” ahead of the Q1 results. It cites valuation for the upgrade following the recent selloff. Sarepta shares now trade within a “reasonable valuation range” ahead of an expected “solid” Q1 report, the analyst tells investors in a research note. H.C. Wainwright still expects Elevidys revenue to fall short of estimates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Marks’ Resignation Is a ‘Blow for Biotech Industry,’ Says RBC Analyst as Biotech Stocks Fall
- Sarepta price target lowered to $179 from $210 at BofA
- Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz
- Biotech stocks slide as Marks resignation seen being negative for sector
- Okta initiated, Wingstop upgraded: Wall Street’s top analyst calls